Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Ablynx Generates Nanobodies against GPCRs

By Drug Discovery Trends Editor | February 2, 2009

Ablynx announced it has successfully generated Nanobodies against several GPCR receptors. Ablynx also announced its preclinical development program ALX-0141, a Nanobody against Receptor Activator for Nuclear Factor kappa B Ligand (RANKL), an important target for bone disorders such as osteoporosis.

Nanobodies are a new class of therapeutic proteins that contain the unique structural and functional properties of naturally-occurring single domain antibodies. Nanobodies have been generated against over 100 different targets now including complex targets such as GPCRs, which are typically difficult to approach with conventional monoclonal antibodies. Nanobody constructs have been generated against GPCRs with picomolar activity in functional cellular assays such as chemotaxis and cell mobility. Ablynx has validated 25 Nanobody programs in relevant in vivo models.
 
ALX-0141 is the first single domain antibody developed by Ablynx that specifically targets RANKL, an essential regulator of osteoclasts, the cells involved in the breakdown of bone. ALX-0141 is now in preclinical development and Ablynx will progress the program towards clinical development for osteoporosis.

www.ablynx.com


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50